Feedback (FDBK) AI Stock Analysis

Feedback

(LSE:FDBK)

Select Model

Rating:46Neutral

Price Target:GBX 6.50▲(18.18% Upside)

Action:reiterated

Date:05/20/26

Feedback plc receives a low overall score of 46, reflecting significant financial challenges. The company's revenue decline and persistent losses are the primary concerns, compounded by bearish technicals and an unattractive valuation. While the balance sheet remains debt-free, the cash burn may necessitate external financing. Investors should approach with caution.

Positive Factors

Debt-free balance sheetFeedback's zero-debt balance sheet meaningfully reduces refinancing and interest-rate risk. For a small digital-health software provider, no financial leverage preserves strategic flexibility and extends runway, allowing management to pursue restructuring or growth without fixed financing obligations.

Negative Factors

Sharp revenue declineA sustained ~25-30% revenue decline materially reduces the addressable recurring base for a SaaS business. Lower recurring sales hinder absorption of fixed operating costs, slow path to profitability, and make it difficult to leverage the company's high gross margins into improved operating results without revenue stabilization.

Feedback (FDBK) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: GBP 2.26M
Dividend Yield: ―
Average Volume (3M): 78.60K
Price to Earnings (P/E): -0.3
Beta (1Y): 1.00
Revenue Growth: -28.82%
EPS Growth: 31.59%
Country: UK
Employees: 29
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

Feedback Business Overview & Revenue Model

Company Description

Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio inc...

How the Company Makes Money

Feedback plc generates revenue primarily by selling and licensing its digital health software to healthcare providers and related organizations. Its core revenue stream is typically recurring software income (e.g., subscription/SaaS or term licences)...

Feedback Financial Statement Overview

Summary

Revenue declined 25.8% in the latest year, with widening losses and negative cash flow. The balance sheet is debt-free and retains some equity, but persistent cash burn raises liquidity concerns. Overall financial health is weak.

Income Statement

10Very Negative

Balance Sheet

20Very Negative

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	May 2024	May 2023	May 2022	May 2021	May 2020
Income Statement
Total Revenue	849.62K	885.62K	1.18M	1.02M	588.58K	287.42K
Gross Profit	535.65K	778.65K	1.10M	131.39K	-63.68K	213.64K
EBITDA	-3.33M	-3.06M	-2.73M	-2.61M	-1.96M	-2.01M
Net Income	-7.18M	-7.32M	-3.30M	-2.92M	-2.12M	-1.62M
Balance Sheet
Total Assets	4.86M	6.75M	8.34M	11.72M	14.30M	5.82M
Cash, Cash Equivalents and Short-Term Investments	3.82M	5.95M	3.88M	7.32M	10.31M	2.22M
Total Debt	0	0	0	0	0	0
Total Liabilities	400.00K	589.02K	694.18K	855.45K	594.13K	552.83K
Stockholders Equity	4.46M	6.16M	7.64M	10.87M	13.71M	5.27M
Cash Flow
Free Cash Flow	-3.30M	-2.83M	-2.14M	-2.99M	-2.41M	-3.47M
Operating Cash Flow	-3.29M	-2.82M	-2.22M	-1.74M	-1.25M	-2.03M
Investing Cash Flow	-725.81K	-716.00K	-1.22M	-1.24M	-1.15M	-1.44M
Financing Cash Flow	496.49K	5.61M	0	-830	10.49M	4.96M

Feedback Technical Analysis

Technical Analysis SentimentNegative

Last Price5.50

Price Trends

50DMA6.52Negative

100DMA6.54Negative

200DMA8.81Negative

Market Momentum

MACD-0.25Positive

RSI26.41Positive

STOCH11.93Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FDBK, the sentiment is Negative. The current price of 5.50 is below the 20-day moving average (MA) of 6.32, below the 50-day MA of 6.52, and below the 200-day MA of 8.81, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 26.41 is Positive, neither overbought nor oversold. The STOCH value of 11.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FDBK.

Feedback Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:FDBK against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:KOO	72Outperform	GBP 69.14M	11.49	17.74%	―	-6.51%	108.62%
GB:IXI	55Neutral	GBP 25.73M	-7.14	-16.18%	―	13.04%	15.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:GDR	49Neutral	GBP 15.65M	-0.89	-1044.57%	―	65.60%	74.84%
GB:COG	47Neutral	GBP 15.11M	-9.30	-54.17%	―	11.86%	23.81%
GB:FDBK	46Neutral	GBP 2.08M	-0.32	-135.17%	―	-28.82%	31.59%
GB:OBD	40Underperform	GBP 14.45M	-0.26	-451.74%	―	33.37%	86.41%

* Healthcare Sector Average

Performance Comparison

GB:FDBK and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:FDBK	Feedback plc	5.15	-3.65	-41.48%
GB:COG	Cambridge Cognition Holdings	28.00	-5.00	-15.15%
GB:GDR	Genedrive plc	0.97	-0.04	-3.75%
GB:IXI	IXICO plc	14.00	2.75	24.44%
GB:OBD	Oxford BioDynamics	0.10	-0.22	-68.13%
GB:KOO	Kooth Plc	189.50	62.50	49.21%

Feedback Corporate Events

Business Operations and StrategyFinancial Disclosures

Feedback plc holds revenue steady as Bleepa gains traction with NHS

Positive

Jul 14, 2026

Feedback plc reported flat revenue of about £0.8m for the year to 31 May 2026 but said its EBITDA loss will be lower than expected thanks to tight cost controls and cash management. Year-end cash of £2.7m came in ahead of forecasts, giving...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: May 19, 2026

Feedback AI Stock Analysis